0001209191-20-031054.txt : 20200520 0001209191-20-031054.hdr.sgml : 20200520 20200520194939 ACCESSION NUMBER: 0001209191-20-031054 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200518 FILED AS OF DATE: 20200520 DATE AS OF CHANGE: 20200520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sharp Shalini CENTRAL INDEX KEY: 0001377202 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36276 FILM NUMBER: 20899611 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc. CENTRAL INDEX KEY: 0001515673 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272546083 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-483-8800 MAIL ADDRESS: STREET 1: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-18 0 0001515673 Ultragenyx Pharmaceutical Inc. RARE 0001377202 Sharp Shalini C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 0 1 0 0 CFO & Executive Vice President Common Stock 2020-05-18 4 M 0 19593 70.57 A 122929 D Common Stock 2020-05-18 4 S 0 19593 73.34 D 103336 D Common Stock 2020-05-18 4 S 0 2392 73.29 D 100944 D Common Stock 2020-05-19 4 M 0 3221 48.43 A 104165 D Common Stock 2020-05-19 4 S 0 3221 73.32 D 100944 D Common Stock 2020-05-19 4 M 0 3907 70.57 A 104851 D Common Stock 2020-05-19 4 S 0 3907 73.32 D 101556 D Stock Option (Right to Buy) 70.57 2020-05-18 4 M 0 19593 0.00 D 2026-06-01 Common Stock 19593 4407 D Stock Option (Right to Buy) 48.43 2020-05-19 4 M 0 3221 0.00 D 2028-03-01 Common Stock 3221 31779 D Stock Option (Right to Buy) 70.57 2020-05-19 4 M 0 3907 0.00 D 2026-06-01 Common Stock 3907 500 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.04 to $73.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.01 to $73.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.05 to $73.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Includes 612 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2020. 1/4th of the option vested one year from June 1, 2016 and then 1/48th of the option vested and will vest monthly thereafter. 1/4th of the option vested one year from March 1, 2018 and then 1/48th of the option vested and will continue to vest monthly thereafter. /s/ Karah Parschauer, attorney-in-fact 2020-05-20